David M. Goldstein
Chief Tech/Sci/R&D Officer bei PRINCIPIA BIOPHARMA INC.
Profil
David M.
Goldstein is currently the Director at Frontier Medicines Corp.
and the Chief Scientific Officer at Principia Biopharma, Inc. He previously worked as the Senior Director-Medicinal Chemistry at Roche Holding AG from 1994 to 2011.
He also worked as a Professor at Stanford University.
Goldstein holds a doctorate degree from the University of Virginia and an undergraduate degree from Franklin & Marshall College.
Aktive Positionen von David M. Goldstein
| Unternehmen | Position | Beginn |
|---|---|---|
| PRINCIPIA BIOPHARMA INC. | Chief Tech/Sci/R&D Officer | 01.01.2016 |
Frontier Medicines Corp.
 Frontier Medicines Corp. Pharmaceuticals: MajorHealth Technology Frontier Medicines Corp. develops medicines that redefine the course of debilitating diseases. The company was founded by Chris Varma, Daniel K. Nomura and Roberto Zoncu in 2018 and is headquartered in South San Francisco, CA. | Director/Board Member | 30.03.2021 |
Ehemalige bekannte Positionen von David M. Goldstein
| Unternehmen | Position | Ende |
|---|---|---|
| ROCHE HOLDING AG | Corporate Officer/Principal | 01.01.2011 |
| Stanford University | Corporate Officer/Principal | - |
Ausbildung von David M. Goldstein
| University of Virginia | Doctorate Degree |
| Franklin & Marshall College | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| ROCHE HOLDING AG | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Principia Biopharma, Inc.
 Principia Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Principia Biopharma, Inc. is a biopharmaceutical company, which engages in designing and developing oral therapies to patients with significant unmet medical needs in immunology and oncology. It operates through Tailored Covalency platform, which enables to develop small molecule inhibitors of enzymes and receptor ligands with potencies and selectivities that rival those of injectable biologics, yet maintain the convenience of a pill. Its product pipeline includes PRN1008, PRN2246, PRN1371, and immunoproteasome inhibitor. The company was founded by Jack Taunton and Richard A. Miller on October 6, 2008 and is headquartered in South San Francisco, CA. | Health Technology |
Frontier Medicines Corp.
Frontier Medicines Corp. Pharmaceuticals: MajorHealth Technology Frontier Medicines Corp. develops medicines that redefine the course of debilitating diseases. The company was founded by Chris Varma, Daniel K. Nomura and Roberto Zoncu in 2018 and is headquartered in South San Francisco, CA. | Health Technology |
